Frequency and severity of hypoglycemia in type 2 diabetes mellitus patients treated with a sulfonylurea-based regimen at university-affiliated hospitals in Korea: The naturalistic evaluation of hypoglycemic events in diabetic subjects study

Yon Su Kim, Be Long Cho, Woo Sik Kim, Sang Hyun Kim, In Hyeon Jung, Won Yong Sin, Dong Hoon Choi, Sang Jae Lee, Chun Soo Lim, Kyung Pyo Kang, Byung Yeon Yu, Wonju Jeung, Chang Gyu Park

Research output: Contribution to journalArticle

Abstract

Background: We assessed the frequency and severity of hypoglycemia in type 2 diabetes mellitus patients treated with sulfonylurea monotherapy or sulfonylurea+metformin. Methods: We conducted a retrospective, observational, cross-sectional study in 2011 and 2012 including patients with type 2 diabetes mellitus aged ≥30 years who were treated with ≥6 months of sulfonylurea monotherapy or sulfonylurea+metformin at 20 university-affiliated hospitals in Korea. At enrollment, glycated hemoglobin (HbA1c) was assessed; participants completed self-reported questionnaires describing hypoglycemia incidents over the past 6 months. A review of medical records up to 12 months before enrollment provided data on demographics, disease history, comorbidities, laboratory results, and drug usage. Results: Of 726 enrolled patients, 719 were included (55.6% male); 31.7% and 68.3% were on sulfonylurea monotherapy and sulfonylurea+metformin, respectively. Mean±standard deviation age was 65.9±10.0 years; mean HbA1c level was 7.0%±1.0%; 77.8% of patients had hypertension (89.4% used antihypertensive medication); 60.5% had lipid disorders (72.5% used lipid-lowering medication); and 52.0% had one or more micro- or macrovascular diseases. Among patients with A1c measurement (n=717), 56.4% achieved therapeutic goals (HbA1c < 7.0%); 42.4% (305/719) experienced hypoglycemia within 6 months of enrollment; and 38.8%, 12.9%, 12.7%, and 3.9% of patients experienced mild, moderate, severe, and very severe hypoglycemia symptoms, respectively. Several reported hypoglycemia frequency as 1-2 times over the last 6 months. The mean number of very severe hypoglycemia episodes was 3.5±5.5. Conclusion: Among type 2 diabetes mellitus patients treated with sulfonylurea-based regimens, glycemic levels were relatively well controlled but hypoglycemia remained a prevalent side effect.

Original languageEnglish
Pages (from-to)212-219
Number of pages8
JournalKorean Journal of Family Medicine
Volume40
Issue number4
DOIs
Publication statusPublished - 2019 Jul 1

Fingerprint

Korea
Hypoglycemia
Hypoglycemic Agents
Type 2 Diabetes Mellitus
Metformin
Lipids
Glycosylated Hemoglobin A
Antihypertensive Agents
Medical Records
Comorbidity
Cross-Sectional Studies
Demography
Hypertension
Pharmaceutical Preparations

Keywords

  • Glycated hemoglobin A
  • Hypoglycemia
  • Metformin
  • Sulfonylurea
  • Type 2 diabetes mellitus

ASJC Scopus subject areas

  • Family Practice

Cite this

Frequency and severity of hypoglycemia in type 2 diabetes mellitus patients treated with a sulfonylurea-based regimen at university-affiliated hospitals in Korea : The naturalistic evaluation of hypoglycemic events in diabetic subjects study. / Kim, Yon Su; Cho, Be Long; Kim, Woo Sik; Kim, Sang Hyun; Jung, In Hyeon; Sin, Won Yong; Choi, Dong Hoon; Lee, Sang Jae; Lim, Chun Soo; Kang, Kyung Pyo; Yu, Byung Yeon; Jeung, Wonju; Park, Chang Gyu.

In: Korean Journal of Family Medicine, Vol. 40, No. 4, 01.07.2019, p. 212-219.

Research output: Contribution to journalArticle

Kim, Yon Su ; Cho, Be Long ; Kim, Woo Sik ; Kim, Sang Hyun ; Jung, In Hyeon ; Sin, Won Yong ; Choi, Dong Hoon ; Lee, Sang Jae ; Lim, Chun Soo ; Kang, Kyung Pyo ; Yu, Byung Yeon ; Jeung, Wonju ; Park, Chang Gyu. / Frequency and severity of hypoglycemia in type 2 diabetes mellitus patients treated with a sulfonylurea-based regimen at university-affiliated hospitals in Korea : The naturalistic evaluation of hypoglycemic events in diabetic subjects study. In: Korean Journal of Family Medicine. 2019 ; Vol. 40, No. 4. pp. 212-219.
@article{46e77b3b59284fbd8aeeee1a0f9f7171,
title = "Frequency and severity of hypoglycemia in type 2 diabetes mellitus patients treated with a sulfonylurea-based regimen at university-affiliated hospitals in Korea: The naturalistic evaluation of hypoglycemic events in diabetic subjects study",
abstract = "Background: We assessed the frequency and severity of hypoglycemia in type 2 diabetes mellitus patients treated with sulfonylurea monotherapy or sulfonylurea+metformin. Methods: We conducted a retrospective, observational, cross-sectional study in 2011 and 2012 including patients with type 2 diabetes mellitus aged ≥30 years who were treated with ≥6 months of sulfonylurea monotherapy or sulfonylurea+metformin at 20 university-affiliated hospitals in Korea. At enrollment, glycated hemoglobin (HbA1c) was assessed; participants completed self-reported questionnaires describing hypoglycemia incidents over the past 6 months. A review of medical records up to 12 months before enrollment provided data on demographics, disease history, comorbidities, laboratory results, and drug usage. Results: Of 726 enrolled patients, 719 were included (55.6{\%} male); 31.7{\%} and 68.3{\%} were on sulfonylurea monotherapy and sulfonylurea+metformin, respectively. Mean±standard deviation age was 65.9±10.0 years; mean HbA1c level was 7.0{\%}±1.0{\%}; 77.8{\%} of patients had hypertension (89.4{\%} used antihypertensive medication); 60.5{\%} had lipid disorders (72.5{\%} used lipid-lowering medication); and 52.0{\%} had one or more micro- or macrovascular diseases. Among patients with A1c measurement (n=717), 56.4{\%} achieved therapeutic goals (HbA1c < 7.0{\%}); 42.4{\%} (305/719) experienced hypoglycemia within 6 months of enrollment; and 38.8{\%}, 12.9{\%}, 12.7{\%}, and 3.9{\%} of patients experienced mild, moderate, severe, and very severe hypoglycemia symptoms, respectively. Several reported hypoglycemia frequency as 1-2 times over the last 6 months. The mean number of very severe hypoglycemia episodes was 3.5±5.5. Conclusion: Among type 2 diabetes mellitus patients treated with sulfonylurea-based regimens, glycemic levels were relatively well controlled but hypoglycemia remained a prevalent side effect.",
keywords = "Glycated hemoglobin A, Hypoglycemia, Metformin, Sulfonylurea, Type 2 diabetes mellitus",
author = "Kim, {Yon Su} and Cho, {Be Long} and Kim, {Woo Sik} and Kim, {Sang Hyun} and Jung, {In Hyeon} and Sin, {Won Yong} and Choi, {Dong Hoon} and Lee, {Sang Jae} and Lim, {Chun Soo} and Kang, {Kyung Pyo} and Yu, {Byung Yeon} and Wonju Jeung and Park, {Chang Gyu}",
year = "2019",
month = "7",
day = "1",
doi = "10.4082/kjfm.18.0051",
language = "English",
volume = "40",
pages = "212--219",
journal = "Korean Journal of Family Medicine",
issn = "2005-6443",
publisher = "Korean Academy of Family Medicine",
number = "4",

}

TY - JOUR

T1 - Frequency and severity of hypoglycemia in type 2 diabetes mellitus patients treated with a sulfonylurea-based regimen at university-affiliated hospitals in Korea

T2 - The naturalistic evaluation of hypoglycemic events in diabetic subjects study

AU - Kim, Yon Su

AU - Cho, Be Long

AU - Kim, Woo Sik

AU - Kim, Sang Hyun

AU - Jung, In Hyeon

AU - Sin, Won Yong

AU - Choi, Dong Hoon

AU - Lee, Sang Jae

AU - Lim, Chun Soo

AU - Kang, Kyung Pyo

AU - Yu, Byung Yeon

AU - Jeung, Wonju

AU - Park, Chang Gyu

PY - 2019/7/1

Y1 - 2019/7/1

N2 - Background: We assessed the frequency and severity of hypoglycemia in type 2 diabetes mellitus patients treated with sulfonylurea monotherapy or sulfonylurea+metformin. Methods: We conducted a retrospective, observational, cross-sectional study in 2011 and 2012 including patients with type 2 diabetes mellitus aged ≥30 years who were treated with ≥6 months of sulfonylurea monotherapy or sulfonylurea+metformin at 20 university-affiliated hospitals in Korea. At enrollment, glycated hemoglobin (HbA1c) was assessed; participants completed self-reported questionnaires describing hypoglycemia incidents over the past 6 months. A review of medical records up to 12 months before enrollment provided data on demographics, disease history, comorbidities, laboratory results, and drug usage. Results: Of 726 enrolled patients, 719 were included (55.6% male); 31.7% and 68.3% were on sulfonylurea monotherapy and sulfonylurea+metformin, respectively. Mean±standard deviation age was 65.9±10.0 years; mean HbA1c level was 7.0%±1.0%; 77.8% of patients had hypertension (89.4% used antihypertensive medication); 60.5% had lipid disorders (72.5% used lipid-lowering medication); and 52.0% had one or more micro- or macrovascular diseases. Among patients with A1c measurement (n=717), 56.4% achieved therapeutic goals (HbA1c < 7.0%); 42.4% (305/719) experienced hypoglycemia within 6 months of enrollment; and 38.8%, 12.9%, 12.7%, and 3.9% of patients experienced mild, moderate, severe, and very severe hypoglycemia symptoms, respectively. Several reported hypoglycemia frequency as 1-2 times over the last 6 months. The mean number of very severe hypoglycemia episodes was 3.5±5.5. Conclusion: Among type 2 diabetes mellitus patients treated with sulfonylurea-based regimens, glycemic levels were relatively well controlled but hypoglycemia remained a prevalent side effect.

AB - Background: We assessed the frequency and severity of hypoglycemia in type 2 diabetes mellitus patients treated with sulfonylurea monotherapy or sulfonylurea+metformin. Methods: We conducted a retrospective, observational, cross-sectional study in 2011 and 2012 including patients with type 2 diabetes mellitus aged ≥30 years who were treated with ≥6 months of sulfonylurea monotherapy or sulfonylurea+metformin at 20 university-affiliated hospitals in Korea. At enrollment, glycated hemoglobin (HbA1c) was assessed; participants completed self-reported questionnaires describing hypoglycemia incidents over the past 6 months. A review of medical records up to 12 months before enrollment provided data on demographics, disease history, comorbidities, laboratory results, and drug usage. Results: Of 726 enrolled patients, 719 were included (55.6% male); 31.7% and 68.3% were on sulfonylurea monotherapy and sulfonylurea+metformin, respectively. Mean±standard deviation age was 65.9±10.0 years; mean HbA1c level was 7.0%±1.0%; 77.8% of patients had hypertension (89.4% used antihypertensive medication); 60.5% had lipid disorders (72.5% used lipid-lowering medication); and 52.0% had one or more micro- or macrovascular diseases. Among patients with A1c measurement (n=717), 56.4% achieved therapeutic goals (HbA1c < 7.0%); 42.4% (305/719) experienced hypoglycemia within 6 months of enrollment; and 38.8%, 12.9%, 12.7%, and 3.9% of patients experienced mild, moderate, severe, and very severe hypoglycemia symptoms, respectively. Several reported hypoglycemia frequency as 1-2 times over the last 6 months. The mean number of very severe hypoglycemia episodes was 3.5±5.5. Conclusion: Among type 2 diabetes mellitus patients treated with sulfonylurea-based regimens, glycemic levels were relatively well controlled but hypoglycemia remained a prevalent side effect.

KW - Glycated hemoglobin A

KW - Hypoglycemia

KW - Metformin

KW - Sulfonylurea

KW - Type 2 diabetes mellitus

UR - http://www.scopus.com/inward/record.url?scp=85069763308&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85069763308&partnerID=8YFLogxK

U2 - 10.4082/kjfm.18.0051

DO - 10.4082/kjfm.18.0051

M3 - Article

AN - SCOPUS:85069763308

VL - 40

SP - 212

EP - 219

JO - Korean Journal of Family Medicine

JF - Korean Journal of Family Medicine

SN - 2005-6443

IS - 4

ER -